Meine Merkliste  

2.920 Aktuelle Fachpublikationen von Future Medicine


Biomarkers for kidney involvement in pediatric lupus

16.06.2015 | Beatrice Goilav; Chaim Putterman; Tamar B Rubinstein, Biomarkers in Medicine, 2015

Lupus nephritis (LN), the renal involvement in systemic lupus erythematosus, is currently diagnosed by histopathology obtained by percutaneous renal biopsy and is associated with increased morbidity and mortality in both adults and children. LN is more prevalent and severe in children, requiring ...


Serum biomarkers predictive of pre-eclampsia

16.06.2015 | Swati Anand; Tanielle Mei Bench Alvarez; W Evan Johnson; M Sean Esplin; Karen Merrell; T Flint Porter; Steven W Graves, Biomarkers in Medicine, 2015

Aim: We sought serum biomarkers predictive of pre-eclampsia (PE). Materials & methods: Sera obtained at 12–14 weeks of pregnancy from 24 cases who later developed PE and 24 controls with uncomplicated pregnancies were processed and analyzed using a serum proteomic approach. Results: Many ...


Genetic variants in arachidonic acid pathway genes associated with NSAIDs-exacerbated respiratory disease

12.06.2015 | Pedro Ayuso; María del Carmen Plaza-Serón; Natalia Blanca-López; Inmaculada Doña; Paloma Campo; Gabriela Canto; José ..., Pharmacogenomics, 2015

Aim: NSAIDs are the most frequent cause of hypersensitivity drug reactions. We have examined the association between NSAIDs-exacerbated respiratory disease (NERD) and genetic variants in arachidonic acid metabolism genes. Patients & methods: We included 250 NERD patients, 260 NSAID-tolerant ...


Update on thiopurine pharmacogenetics in inflammatory bowel disease

12.06.2015 | Rebecca L Roberts; Murray L Barclay, Pharmacogenomics, 2015

Azathioprine and 6-mercaptopurine remain pivotal therapies for the maintenance of disease remission in patients with Crohn's disease and ulcerative colitis. While thiopurine S-methyltransferase deficiency was the first pharmacogenetic phenomenon to be recognized to influence thiopurine toxicity ...


Release of (and lessons learned from mining) a pioneering large toxicogenomics database

12.06.2015 | Komal S Sandhu; Vamsi Veeramachaneni; Xiang Yao; Alex Nie; Peter Lord; Dhammika Amaratunga; Michael K McMillian; Gee ..., Pharmacogenomics, 2015

Aim: We release the Janssen Toxicogenomics database. This rat liver gene-expression database was generated using Codelink microarrays, and has been used over the past years within Janssen to derive signatures for multiple end points and to classify proprietary compounds. Materials & methods: The ...


Strategies for implementation of an effective pharmacogenomics program in pharmacy education

12.06.2015 | U Subrahmanyeswara Rao; Susan L Mayhew; Prema S Rao, Pharmacogenomics, 2015

Sequencing of the human genome and the evidence correlating specific genetic variations to diseases have opened up the potential of genomics to more effective and less harmful interventions of human diseases. A wealth of pharmacogenomics knowledge is in place for the practice of precision ...


Third Annual Open Meeting of the UK Pharmacogenomics and Stratified Medicine Network Conference

12.06.2015 | Elizabeth H Bradshaw, Pharmacogenomics, 2015

The third Annual Open Meeting of the UK Pharmacogenetics and Stratified Medicine Network was held on 14 January 2015 in association with the Wellcome Trust on the Wellcome Trust Genome Campus at Hinxton, Cambridge, UK. In the morning, speakers from Cancer Research UK, the Medical Research ...


Multigene predictors of tacrolimus exposure in kidney transplant recipients

12.06.2015 | Rebecca A Pulk; David S Schladt; William S Oetting; Weihua Guan; Ajay K Israni; Arthur J Matas; Rory P Remmel; Pamal ..., Pharmacogenomics, 2015

Aim: Determine the effect of the genetic variants beyond CYP3A5*3 on tacrolimus disposition. Patients & methods: We studied genetic correlates of tacrolimus trough concentrations with POR*28, CYP3A4*22 and ABCC2 haplotypes in a large, ethnically diverse kidney transplant cohort (n = 2008). ...


Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye

10.06.2015 | Fabio Salvatore Macaluso; Vincenza Calvaruso; Antonio Craxì, Future Microbiology, 2015

ABSTRACT  Eradication of HCV in patients with advanced liver fibrosis or cirrhosis reduces, but does not altogether abolish, the risk of development of hepatocellular carcinoma. The reasons underlying this residual risk remain elusive. Even if HCV clearance eliminates its direct and indirect ...


Latent tuberculosis infection as a target for tuberculosis control

10.06.2015 | Frank van Leth; Reinout van Crevel; Miranda Brouwer, Future Microbiology, 2015

Future Microbiology June 2015, Vol. 10, No. 6, Pages 905-908.


Seite 3 von 292
Suche per e-Mail abonnieren

Sie erhalten passend zu Ihrer Suche die neusten Suchergebnisse per E-Mail. Dieser Service ist für Sie kostenlos und kann jederzeit abbestellt werden.

Ihr Bowser ist nicht aktuell. Microsoft Internet Explorer 6.0 unterstützt einige Funktionen auf Chemie.DE nicht.